A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
Inclusion Criteria:
Participant must be a minimum of 20 years of age for the investigative sites in Japan.
Are seeking treatment and are motivated to stop or cut down on drinking.
Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as
Exclusion Criteria:
Have evidence of current or within the past 180 days prior to screening (V1), history of any substance use disorder(s) of any severity with a pattern of persistent illicit or nonprescribed substance use as indicated by clinical interview, except alcohol, nicotine, or caffeine.
Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 6 months, or have answered "yes" to any of the suicide-related behaviors on the "Suicidal Behavior" portion of the C-SSRS and the behavior occurred within the past 6 months
Have either of the following:
Have participated in a clinical study and have received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening (V1).
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Birmingham, Alabama 35215, United States
205-876-2601
Los Angeles, California 90095, United States
San Francisco, California 94158, United States
Lakeland, Florida 33803, United States
Baltimore, Maryland 21229, United States
Rockville, Maryland 20853, United States
Philadelphia, Pennsylvania 19104, United States
Seattle, Washington 98195, United States
Kluisbergen, 9690, Belgium
32 496 376259
Beijing, 100088, China
Cheng Du Shi, 610041, China
18980601715
Hangzhou, 310016, China
Shinjuku-ku, 160-0004, Japan
Shinjuku-ku, 169-0072, Japan
Yoshinogari-cho, Kanzaki-gun, 842-0192, Japan
Namdong-gu, 21565, South Korea
+82-32-458-2778
Seoul, 06591, South Korea
Uijeongbu-si, 11765, South Korea
London, SE5 9RS, United Kingdom
Manchester, M25 3BL, United Kingdom
501-221-8681
310-794-5383
858-278-3647
863-940-2087
407-500-5252
305-300-2623
305-705-4111
813-800-5252
401-435-8950
215-746-1943
605-504-3154
214-645-6950
214-396-4844
801-928-3292
32 496 376259
003215792797
32 496 376259
+86 13458529130
86-0571-85127129
13952852603